Application of proteomics in cancer: recent trends and approaches for biomarkers discovery

YW Kwon, HS Jo, S Bae, Y Seo, P Song, M Song… - Frontiers in …, 2021 - frontiersin.org
Proteomics has become an important field in molecular sciences, as it provides valuable
information on the identity, expression levels, and modification of proteins. For example …

Dissecting the dual role of AMPK in cancer: from experimental to human studies

G Zadra, JL Batista, M Loda - Molecular cancer research, 2015 - AACR
The precise role of 5′ AMP-activated kinase (AMPK) in cancer and its potential as a
therapeutic target is controversial. Although it is well established that activation of this …

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

MB Nilsson, Y Yang, S Heeke, SA Patel, A Poteete… - Cancer Cell, 2023 - cell.com
Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients
with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR …

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

MB Nilsson, H Sun, J Robichaux, M Pfeifer… - Science translational …, 2020 - science.org
Acquired resistance to tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor
(EGFR) remains a clinical challenge. Especially challenging are cases in which resistance …

Epithelial–mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints …

Y Lou, L Diao, ERP Cuentas, WL Denning, L Chen… - Clinical Cancer …, 2016 - AACR
Purpose: Promising results in the treatment of non–small cell lung cancer (NSCLC) have
been seen with agents targeting immune checkpoints, such as programmed cell death 1 (PD …

IL6 mediates suppression of T-and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC

SA Patel, MB Nilsson, Y Yang, X Le, HT Tran… - Clinical Cancer …, 2023 - AACR
Purpose: Patients with advanced non–small cell lung cancer (NSCLC) harboring activating
EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However …

Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway

BH Chen, CH Hsieh, SY Tsai, CY Wang, CC Wang - Scientific reports, 2020 - nature.com
Abstract Epigallocatechin-3-gallate (EGCG), a green tea–derived polyphenol, exhibits
antitumor activities. An EGCG nanoemulsion (nano-EGCG) was prepared to improve the …

Chronic obstructive pulmonary disease and lung cancer: new molecular insights

IM Adcock, G Caramori, PJ Barnes - Respiration, 2011 - karger.com
Both chronic obstructive pulmonary disease (COPD) and lung cancer are major causes of
death worldwide. In most cases this reflects cigarette smoke exposure which is able to …

The Effect of Flammulina velutipes Polysaccharide on Immunization Analyzed by Intestinal Flora and Proteomics

Q Liang, Q Zhao, X Hao, J Wang, C Ma, X Xi… - Frontiers in …, 2022 - frontiersin.org
Proteomics and intestinal flora were used to determine the mechanism of immune
modulatory effects of Flammulina velutipes polysaccharide on immunosuppressed mice …

Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer

RJ Cardnell, Y Feng, L Diao, YH Fan, F Masrorpour… - Clinical cancer …, 2013 - AACR
Purpose: Small cell lung carcinoma (SCLC) is an aggressive malignancy affecting nearly
30,000 people annually in the United States. We have previously identified elevated PARP1 …